Inflammatory leukocytes associated with increased immunosuppression by glioblastoma.
In order to determine the in vivo immune response in glioblastoma, monoclonal and polyclonal antibodies specific for inflammatory leukocytes and immunoregulatory products were utilized to stain tissue from four surgical specimens. The more activated the inflammatory cells, the more activated the tumors appeared to be. In the tumor with the largest infiltration (Case 3), inflammatory cells were stained for interferon-gamma, interleukin-2, interleukin-1 beta, lymphotoxin, tumor necrosis factor-alpha, and transforming growth factor-beta. The tumor cells also expressed interleukin-1 beta, interleukin-6, transforming growth factor-beta, tumor necrosis factor-alpha, and prostaglandin E. In contrast, in the tumor with the least inflammatory response (Case 1), the tumor cells did not express any cytokines. Expression of cytokines by glioma cells was modest in the two cases with modest inflammatory responses. Cellular inflammation, primarily consisting of T cells and macrophages with few or no B cells or natural killer cells, was two- to 15-fold greater outside the tumor than within. In contrast to leukocytes outside the tumor, which were activated and expressing class II major histocompatibility antigens, leukocytes within the tumor parenchyma or at the tumor's edge were negative for these antigens. In the four specimens studied here, the tumor cells themselves were also negative for class II major histocompatibility antigens. These findings, although preliminary, suggest that inflammatory cells within gliomas are inactivated and that glioma cells may increase the expression of immunosuppressive cytokines in response to an increased lymphocyte infiltrate. This observation, if corroborated by more extensive studies, may help to explain the failure of immune treatments in glioblastoma multiforme.
Black
K L
KL
Brain Research Institute, Jonnson Cancer Center, Los Angeles, California.
Chen
K
K
Becker
D P
DP
Merrill
J E
JE
D000328:Adult; D001932:Brain Neoplasms / Q000276:immunology*; D016207:Cytokines / Q000032:analysis*; D005260:Female; D005909:Glioblastoma / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance; D007124:Immunoenzyme Techniques; D016130:Immunophenotyping; D007249:Inflammation / Q000276:immunology; D007962:Leukocytes / Q000276:immunology*; D008297:Male; D008875:Middle Aged
D016207:Cytokines